MRK-C

MRK-C is a small molecule research compound developed by Merck (Merck Sharp & Dohme). It was identified as a structurally similar control compound during the discovery and characterization of MRK-A, a potent inhibitor of the YAP1/TAZ-TEAD transcriptional complex. In biochemical and cellular assays, MRK-C demonstrated no significant activity against TEAD-mediated transcription, with an IC50 greater than 10,000 nM in TEAD reporter assays. Furthermore, MRK-C did not impact the clonogenic growth or viability of NF2-deficient mesothelioma cell lines, such as H226. It serves as an inactive negative control to validate the target specificity and biological effects of aryl ether-based Hippo pathway inhibitors.